OncoMatch/Clinical Trials/NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Is NCT06911502 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for follicular lymphoma.
Treatment: Golcadomide · Rituximab · Lenalidomide · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone/Prednisolone · Bendamustine — The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Must have received: combination including an anti-cd20 monoclonal antibody and an alkylating agent (rituximab, obinutuzumab, cyclophosphamide, bendamustine)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1,000 cells/mm3; platelet count ≥ 75,000 cells/mm3; hemoglobin ≥ 7.5 g/dl
Kidney function
estimated glomerular filtration rate (egfr) ≥ 30 ml/min/1.73m²
Liver function
serum aspartate transaminase (ast/sgot) or alanine transaminase (alt/sgpt) ≤ 2.5 x uln (≤ 5.0× uln if liver involvement); serum total bilirubin ≤ 1.5 × uln (≤ 3.0 × uln if liver involvement; ≤ 5.0 × uln for gilbert's syndrome)
Cardiac function
adequate cardiac function for anthracycline-based chemotherapy: lvef ≥ 45% by echo or muga
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0225 · Birmingham, Alabama
- Infirmary Cancer Care · Mobile, Alabama
- Alaska Oncology and Hematology · Anchorage, Alaska
- Local Institution - 0215 · Little Rock, Arkansas
- City of Hope Comprehensive Cancer Center · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06911502 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and combination including an anti-cd20 monoclonal antibody and an alkylating agent.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages